	<u> </u>		
A. CLASS	IFICATION OF SUBJECT MATTER C17 A61K31/416, 31/4439, 31/444	31/497. A61P3/10. 9/	00;
Int.	9/10, 21/00, 25/00, 25/14,	25/16, 25/28, 43/00,	
	cn7n231/56, 401/06, 401/14,	, 409/14, 403/12	
According to	International Patent Classification (IPC) or to both nati	Onal classification and IFC	
B. FIELDS	SEARCHED	v classification symbols)	
Minimum do	ocumentation searched (classification system followed by C1 <sup>7</sup> A61K31/416, 31/4439, 31/444	1, 31/43/, MOIP3/10, 3/	00,
11101	9/10, 21/00, 25/00, 25/14,	25/16, 25/28, 43/00,	
	C07D231/56, 401/06, 401/14,		
Documentati	ion searched other than minimum documentation to the	extent that such documents are included	in the fields searched
		Classical whom continues con	rob terms used)
Electronic d	ata base consulted during the international search (name CAS, JOIS	of data base and, where practicable, seal	ch terms used)
SIN	CAS, 0013		,
			, : 
C. DOCU	MENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.
X	WO 02/10137 A2 (SIGNAL PHARM)		1-4,6-10,
^	07 February, 2002 (07.02.02),		17-18,20-22
Y	& US 2002/103229 A1 & EP	1313711 A2	5,19
Y	YANG, D.D. et al., "Absence o	f excitotoxicity-	5,19
}	induced apoptosis in the hipp	ocampus of mice	
	lacking the Jnk3 gene", Natur	e, Vol.389,	
	pages 865 to 870, (1997)		
х	WO 01/53268 A2 (AGOURON PHAR	MACEUTICALS, INC.),	2,9 1,3-8,17-22
A	26 July, 2001 (26.07.01), & EP 1250326 A2 & US	2002/161022 A1	1,3-0,17-22
	& US 6555539 B2 & BR	2001007783 A	
	& JP 2003-520273 A & EE	200200398 A	
D	& NO 2002002117 A & BR	10/011 A	,
	& US 2003/139463 Al		
Further documents are listed in the continuation of Box C. See patent family annex.			
Speci	al categories of cited documents:	"T" later document published after the in	ternational filing date or
"A" docur	"A" document defining the general state of the art which is not considered to be of particular relevance carlier document but published on or after the international filing carlier document of particular relevance; the claimed invention cannot be considered to involve an inventive		
"E" carlic			
"L" docur	ment which may throw doubts on priority claim(s) or which is	step when the document is taken alor "Y" document of particular relevance; the	ne
cited	to establish the publication date of another citation or other	considered to involve an inventive st	ep when the document is
"O" docum	ment referring to an oral disclosure, use, exhibition or other	combined with one or more other suc combination being obvious to a person	on skilled in the art
l "P" docui	ment published prior to the international filing date but later the priority date claimed	"&" document member of the same paten	t tamily .
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report
10 February, 2004 (10.02.04) 24 February, 2004 (24.02.04)		(24.02.04)	
	·		
Name and	mailing address of the ISA/	Authorized officer	
Jap	anese Patent Office		

Telephone No.

Facsimile No.

## INTERNATIONAL SEARCH REPORT

Internation optication No.
PCT/JP03/15481

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
.X A	JP 2-32059 A (Kyowa Hakko Kogyo Co., Ltd.), 01 February, 1990 (01.02.90), (Family: none)	2,9 1,3-8,17-22
P,X	WO 03/101968 Al (Eisai Co., Ltd.), 11 December, 2003 (11.12.03), (Family: none)	1-4,6-10, 17-18,20-22
A	WO 2001/02369 A2 (AGOURON PHARMACEUTICALS, INC.), 11 January, 2001 (11.01.01), 6 BR 2000012352 A & EP 1218348 A2 6 JP 2003-503481 A & NZ 516676 A 6 US 6531491 B1 & US 6534524 B1 6 NO 2001005797 A & ZA 2001010061 A	1-10,17-22
	& NO 2001005797 A & ZA 2001010061 A & BR 106380 A	

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1. X Claims Nos.: 11 to 16  because they relate to subject matter not required to be scarched by this Authority, namely:		
The inventions as set forth in claims 11 to 16 are relevant to method fo treatment of the human body by therapy.		
2. Claims Nos.:		
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3. Claims Nos.:		
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows:		
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchab claims.		
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite paymen		
of any additional fee.		
3. As only some of the required additional search fees were timely paid by the applicant, this international search report cove		
only those claims for which fees were paid, specifically claims Nos.:		
*		
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is		
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
Remark on Protest The additional search fees were accompanied by the applicant's protest.		
No protest accompanied the payment of additional search fees.		
The protest accompanies are payment of a contract of the payment o		